Auxilius Pharma is a cardiovascular biotech that reformulates existing drug compounds through the FDA's 505(b)(2) pathway. Its lead candidate AUX-001 is a once-daily extended-release nicorandil for chronic stable angina, a category with no new US approval since 2006. Headquartered in Krakow.